Cencora, Inc. (NYSE:COR) Shares Sold by Dakota Wealth Management

Dakota Wealth Management lessened its position in Cencora, Inc. (NYSE:COR) by 14.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,169 shares of the company’s stock after selling 6,650 shares during the period. Dakota Wealth Management’s holdings in Cencora were worth $9,025,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of COR. Insight Wealth Strategies LLC raised its position in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after buying an additional 11,232 shares during the period. Cerity Partners LLC grew its stake in Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after purchasing an additional 3,610 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Portfolio Design Labs LLC bought a new stake in shares of Cencora during the 3rd quarter worth about $1,404,000. Finally, Mackenzie Financial Corp boosted its stake in shares of Cencora by 9.9% during the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock worth $18,250,000 after acquiring an additional 7,266 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on COR. Mizuho started coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Evercore ISI increased their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Leerink Partners cut their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,187 shares of company stock valued at $17,790,912. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 1.3 %

Shares of COR opened at $245.21 on Wednesday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The stock has a 50 day simple moving average of $237.38 and a 200-day simple moving average of $234.15. The stock has a market cap of $47.39 billion, a PE ratio of 32.65, a PEG ratio of 1.51 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. Cencora’s dividend payout ratio is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.